Maravai LifeSciences Holdings, Inc. Class A Common Stock
Here’s whether Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+5.20% over 10 days); strong 1-year return of +119.2%; 3-month momentum positive (+37.4%). Concerns: below the 50-day MA (medium-term momentum negative); RSI 20 — oversold. Currently 23.4% off its 52-week high. Score: +3/7.
MRVI is holding above its long-term 200-day MA ($4.16) but has slipped below the 50-day MA ($6.05), pointing to short-term weakness in an otherwise intact trend. An RSI of 20.4 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +119.2% compares to +20.4% for SPY (beat the market by 98.9%). The current 23.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.